Private drug discovery company Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.

San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.